Full-Time

Clinical Operations Director

Clinical Operations

5AM Ventures

5AM Ventures

11-50 employees

Venture capital investing in life-science innovations

Compensation Overview

$210k - $270k/yr

Berkeley, CA, USA

Remote

Remote role; based at Berkeley, California, with no on-site requirement.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to 5AM Ventures

See people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences or related field; advanced degree preferred.
  • 10+ years of clinical operations experience (15+ for Senior Director)
  • Experience leading clinical studies from startup through database lock and study closeout.
  • Experience in rare disease, nephrology, ADPKD, genetic disease, or other specialized patient populations.
  • Experience with clinical studies requiring genetic testing, genetic confirmation of diagnosis, or genomics-driven patient identification.
  • Strong experience managing CROs and external vendors in outsourced operating models.
  • Demonstrated success leading study startup activities and global site activation efforts.
  • Experience developing study budgets, timelines, and operational risk management plans.
  • Strong knowledge of ICH-GCP, FDA, EMA, and global clinical trial regulations.
  • Excellent communication, leadership, and cross-functional collaboration skills.
Responsibilities
  • Design and implement scalable clinical operations processes, governance structures, vendor oversight models, and study management practices.
  • Establish the framework for how Renasant executes clinical trials as the organization grows.
  • Evaluate which functions should be maintained internally and which should be outsourced to CROs and specialized vendors.
  • Support future hiring plans and organizational design for Clinical Operations.
  • Support clinical studies involving genetically defined patient populations and genetic confirmation of diagnosis.
  • Develop operational approaches for patient identification, screening, and enrollment in rare disease populations.
  • Establish relationships with nephrology investigators, rare disease centers of excellence, patient advocacy organizations, and specialty testing partners.
  • Support global recruitment strategies where patient populations may be geographically dispersed.
  • Lead selection, oversight, and performance management of CROs, central laboratories, genetic testing vendors, imaging vendors, and specialty providers.
  • Establish clear governance structures and accountability measures for external partners.
  • Ensure external partners function as extensions of the Renasant team while maintaining high standards of quality, speed, and execution.
  • Serve as the primary Clinical Operations leader responsible for transitioning programs from preclinical and translational development into clinical execution.
  • Partner with DMPK, Toxicology, and Research teams to develop operationally feasible clinical development plans.
  • Identify operational risks, and execution challenges before studies enter the clinic.
  • Provide operational input into protocol development, patient identification approaches, and study feasibility.
  • Build operational strategies for first-in-human and proof-of-concept studies.
  • Lead feasibility assessments, country selection, site identification, enrollment planning, and vendor selection activities.
  • Develop study timelines, budgets, risk mitigation plans, and execution strategies.
  • Oversee and execute study startup through database lock and study closeout.
Desired Qualifications
  • Experience supporting global clinical trials, including sites outside the United States.
  • Experience building or scaling clinical operations functions within emerging biotechnology companies.
  • Experience supporting regulatory inspections and audit readiness activities.
  • Experience with decentralized or hybrid clinical trial models.

5AM Ventures is an investment firm focused on backing advanced life science innovations. It diversifies its bets across biopharmaceutical therapeutics and platform technologies, investing within multiple therapeutic areas and modalities. Its approach targets opportunities built on innovative platform platforms, corporate spin-offs, and products with shorter development timelines. The firm’s “product” is providing capital, strategic guidance, and resources to portfolio companies to help them reach clinically or commercially viable milestones faster. Unlike some investors that emphasize a single niche, 5AM differentiates itself by breadth across life science sectors and a focus on technologies with the potential for quicker development cycles. The firm’s goal is to create value by supporting responsible, science-driven progress in life sciences and helping portfolio companies advance promising therapies and platforms to patients and markets.

Company Size

11-50

Company Stage

N/A

Total Funding

$9.2B

Headquarters

Menlo Park, California

Founded

2002

Get referred to 5AM Ventures

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Precede Biosciences raised $83.5M by January 2026, validating 5AM's diagnostics thesis.
  • Artiva reported positive autoimmune data and FDA alignment for Phase 3 in 2026.
  • Arvinas won FDA approval for VEPPANU on April 28, 2026, boosting portfolio credibility.

What critics are saying

  • Biotech exits stay fragile; Dianthus Therapeutics exited 2026 after an entire stake sale.
  • Public-market exposure cuts both ways; Entrada sold $807,027 shares on July 30, 2026.
  • If 4:59 stops producing breakout companies, 5AM loses its core venture edge.

What makes 5AM Ventures unique

  • 5AM Ventures backs Series A therapeutics and builds companies through its 4:59 incubator.
  • The firm spans biopharma, drug delivery, and research tools, not pure therapeutics.
  • 5AM still controls $450M VII and $300M Opportunities II as of 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Remote Work Options

Hybrid Work Options

Flexible Work Hours

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

PTO/vacation is mentioned? Not explicitly; will not assume beyond listed items

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Fertility Treatment Support

Family Planning Benefits

Adoption Assistance

Parental Leave

Stock Options

Company Equity

Education allowance

Professional Certification Support

Tuition Reimbursement

Mentorship Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Wellness Program

Mental Health Support

Company News

GlobeNewswire
Jul 20th, 2026
Nouscom selected for oral presentation on NOUS-209 re-treatment and long-term follow-up in Lynch Syndrome carriers at ESMO Congress 2026.

Nouscom selected for oral presentation on NOUS-209 re-treatment and long-term follow-up in Lynch Syndrome carriers at ESMO Congress 2026. July 20, 2026 07:00 ET | Source: Nouscom Srl * New data from the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 * NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions of LS carriers * The presentation will report the safety and immunogenicity of NOUS-209 re-treatment, together with clinical follow-up extending beyond one year * Follows the recent U.S. FDA Fast Track Designation (FTD) for NOUS-209 and reinforces Nouscom's momentum toward initiation of a registration-enabling trial BASEL, Switzerland - July 20, 2026 - Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that new data from its Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The oral presentation, titled "Safety and Immunogenicity of Re-vaccination with Nous-209: a neoantigen vaccine for cancer interception in Lynch syndrome carriers," will be given by Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center. It will report the safety and immunogenicity of NOUS-209 re-treatment alongside clinical follow-up extending beyond one year, further reinforcing the strength and durability of the data supporting NOUS-209 as a potential cancer interception immunotherapy for LS carriers. "This is yet another recognition of the outstanding data we have generated for NOUS-209 in Lynch Syndrome - the fourth oral presentation of data from this trial, following AACR 2025 and SITC 2023 and 2025," said Marina Udier, Ph.D., Chief Executive Officer of Nouscom. "Together with our recent FDA Fast Track Designation, it strengthens our conviction and momentum as we advance NOUS-209 into a registration-enabling trial to deliver the first cancer interception immunotherapy for Lynch Syndrome carriers who face up to 80% lifetime risk of developing cancer." The NOUS-209 cancer interception program is supported by Phase 1b/2 data in LS carriers published in Nature Medicine (D'Alise et al., 2026), demonstrating that NOUS-209 was safe and induced broad, potent, functional and durable T cell responses, boosted by annual re-treatment, with no new advanced adenomas detected one year post-treatment - providing the first clinical evidence of cancer interception in LS carriers. The clinical trial NCT05078866 was a collaborative effort between the National Cancer Institute's Cancer Prevention Clinical Trials Network (CP-CTNet) and the iCAN-PREVENT consortium at MD Anderson. The NCI, part of the National Institutes of Health, provided primary funding through Award Number UG1-CA-242609, with additional support from the Data Management, Auditing, and Coordination Center (grant U24CA242637). About NOUS-209 NOUS-209 is an investigational off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency (dMMR) and microsatellite instability (MSI). These tumors are characterized by unique markers known as frameshift peptide (FSP) neoantigens, which are unique to cancerous cells and absent in healthy cells. NOUS-209 comprises two proprietary viral vectors able to deliver 209 shared FSP neoantigens and train the immune system to recognize and attack cancerous and precancerous cells before tumors can develop. Phase 1b/2 data demonstrated the safety of NOUS-209 and its ability to stimulate potent immune responses in LS carriers[1,2], supporting its advancement into a registration-enabling Phase 2/3 trial in cancer interception. NOUS-209 is also being studied in Phase 2 studies in combination with pembrolizumab in a difficult-to-treat patient population of advanced dMMR and/or MSI-H metastatic CRC (mCRC) patients refractory to anti-PD-1 therapy[3] and in first-line treatment of advanced dMMR and/or MSI-H mCRC. Data from the successfully completed Phase 1b trial were published in Science Translational Medicine[4]. About Lynch Syndrome Lynch Syndrome (LS) is a common inherited condition that significantly increases a person's risk of developing cancer over their lifetime, especially colorectal cancer (CRC) (up to 50% risk, compared to 2% for general population), endometrial cancer (up to 50% risk, compared to 1-2% for general population) and urothelial cancer (up to 25% risk, compared to 1-2% for general population)[5,6,7,8]. LS also elevates the risk of developing other cancers including gastric, ovarian, prostate and pancreatic. LS is caused by inherited mutations in specific genes responsible for repairing DNA, leading to the buildup of harmful genetic errors that can accumulate, triggering development of tumors. Currently, managing LS is limited to frequent screenings such as colonoscopy to catch cancer early, but is not shown to reduce cancer incidence[9], and elective surgery, which is invasive, expensive, and negatively impacts quality of life. As a pioneering approach to cancer interception, Nouscom's investigational immunotherapy, NOUS-209, is designed to train the immune system to recognize and stop cancer before it develops. About Cancer Interception Cancer interception is an innovative approach that aims to stop cancer in its earliest stages before tumors fully develop and spread. Unlike traditional therapies that target established cancers, interception strategies harness advancements in immuno-oncology that can train the immune system to recognize and eliminate precancerous and cancerous cells. This approach is particularly relevant for those with high-risk genetic conditions such as LS who have high predisposition to developing MSI-associated cancers. About Nouscom Nouscom is a clinical-stage biotech company pioneering next-generation neoantigen-targeted immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease. Its proprietary viral vector platform enables broad and durable immune activation by delivering optimized neoantigens that train the immune system to recognize and fight cancer. Nouscom's lead program, NOUS-209, is an off-the-shelf immunotherapy in advanced clinical development for cancer interception in LS and the treatment of MSI mCRC. The company's clinical stage portfolio also includes NOUS-PEV, a personalized neoantigen immunotherapy, with published data from a successfully completed Phase 1b trial[10]. Nouscom's current investors include 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, EQT Life Sciences, Indaco Venture Partners SGR, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures and XGEN Ventures. References * D'Alise, AM. et al. Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial. Nature Medicine (2026); DOI: 10.1038/s41591-025-04182-9. * Willis et al, Cancer Res (2025) 85 (8_Supplement_1): 6427. * Abstract is available on the ESMO website, here. * D'Alise et al., Science Translational Medicine, 2022. * Dominguez-Valentin et al., Genetics in Medicine, 2020. * Dominguez-Valentin et al., The Lancet, 2023. * Strafford, Reviews in Obstetrics & Gynecology, 2012. * Richters et al., World Journal of Urology, 2020. * Ahadova et al., International Journal of Cancer 2020. * D'Alise et al., Clin Cancer Research, 2024. MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallow [email protected] +44 (0)203 928 6900 Company Profile Nouscom Srl Industry: Health Care Equipment & Services Website: http://www.nouscom.com Recommended reading.

医谷手机网
Apr 22nd, 2026
IDEAYA raises $46M Series A from Canaan Partners, Celgene and Novartis for cancer immunotherapy

IDEAYA Biosciences, a California-based biotech company, has raised $46 million in a Series A round led by 5AM Ventures and Canaan Partners. Participants include Celgene, Novartis Institute of Biomedical Research, Alexandria Real Estate, and Chinese firm YuChengTM Capital. The funding will advance IDEAYA's development of synthetic lethality therapies and cancer immunotherapies. The company is developing small molecule drugs targeting immune function inhibitors that can activate the immune system or modify the tumour microenvironment. IDEAYA's advisory board includes 2011 Nobel Prize winner Bruce Beutler and two National Academy of Sciences members. Co-founder and CEO Yujiro Hata previously worked at Flexus Bioscience, which was acquired for $1.25 billion. The company aims to advance its programmes towards candidate selection and clinical trials.

StockTitan
Jan 30th, 2026
Biotech ALX Oncology raises $150M to fund cancer drug trials

Offering prices 76.9M shares at $1.57 plus pre-funded warrants, raising ~$150M to advance ALX Oncology’s evorpacept and ALX2004 trials.

Business Wire
Jan 23rd, 2026
Mendra Launches with $82 Million Series A to Acquire, Develop, and Commercialize Therapeutics for High Unmet Need Rare Diseases

Mendra, Inc. (“Mendra”), a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI),...

Kinaset Therapeutics
Jan 12th, 2026
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases — Kinaset Therapeutics

Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment